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Exploring the Association Between Rosacea
and Parkinson Disease
A Danish Nationwide Cohort Study
Alexander Egeberg, MD, PhD; Peter Riis Hansen, MD, PhD, DMSci; Gunnar H. Gislason, MD, PhD;
Jacob P. Thyssen, MD, PhD, DMSci
IMPORTANCE The pathogenesis of rosacea is unclear, but increasedmatrix metalloproteinase
target tissue activity appears to play an important role. Parkinson disease and other
neurodegenerative disorders also display increasedmatrix metalloproteinase activity that
contribute to neuronal loss.
OBJECTIVE To investigate the risk of incident (new-onset) Parkinson disease in patients with
rosacea.
DESIGN, SETTING, AND PARTICIPANTS A nationwide cohort study of the Danish population
was conducted using individual-level linkage of administrative registers. All Danish citizens
18 years or older from January 1, 1997, to December 31, 2011 (N = 5 472 745), were included.
Data analysis was conducted from June 26 to July 27, 2015.
MAIN OUTCOMES ANDMEASURES Themain outcomewas a diagnosis of Parkinson disease.
Incidence rates (IRs) per 10000 person-years were calculated, and incidence rate ratios
(IRRs) adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, medication, and
comorbidity were estimated by Poisson regressionmodels.
RESULTS A total of 5 404692 individuals were included in the reference population; of these,
22 387 individuals (9812 [43.8%] women; mean [SD] age at diagnosis, 75.9 [10.2] years)
received a diagnosis of Parkinson disease during the study period and 68053 individuals
(45 712 [67.2%] women; mean age, 42.2 [16.5] years) were registered as having rosacea.
The IRs of Parkinson disease per 10000 person-years were 3.54 (95% CI, 3.49-3.59) in the
reference population and 7.62 (95% CI, 6.78-8.57) in patients with rosacea. The adjusted IRR
of Parkinson disease was 1.71 (95%, CI 1.52-1.92) in patients with rosacea compared with the
reference population. There was a 2-fold increased risk of Parkinson disease in patients
classified as having ocular rosacea (adjusted IRR, 2.03 [95% CI, 1.67-2.48]), and tetracycline
therapy appeared to reduce the risk of Parkinson disease (adjusted IRR, 0.98 [95% CI,
0.97-0.99]).
CONCLUSIONS AND RELEVANCE Rosacea constitutes an independent risk factor for Parkinson
disease. This association could be due to shared pathogenic mechanisms involving elevated
matrix metalloproteinase activity. The clinical consequences of this association require
further study.
JAMA Neurol. 2016;73(5):529-534. doi:10.1001/jamaneurol.2016.0022
Published online March 21, 2016.
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R osacea is a common chronic inflammatory skin condi-tion characterized primarily by transient or persistentcentrofacial erythema as well as concomitant telangi-
ectasia, papules, and pustules. However, distinct clinical pat-
ternsexistandtheNationalRosaceaSocietyExpertCommittee1
recognizes 4 subtypes of rosacea that frequently overlap:
(1) erythematotelangiectatic, (2) inflammatory papulopustu-
lar, (3) phymatous, and (4) ocular. Topical anti-inflammatory
antibiotics, azelaic acid, or retinoids constitute theusual first-
line therapies, and systemicdrugswith anti-inflammatory ef-
fects, suchas tetracyclinesand isotretinoins, areused formod-
erate to severe rosacea.1,2
Although the etiopathogenesis of rosacea is not fully
understood, the condition has a genetic component.3 More-
over, distinct environmental triggers, including Demodex
folliculorum, UV irradiation, temperature changes, and alco-
hol consumption, have been identified.1 Rosacea skin shows
anupregulationof various cytokines, inparticular, antimicro-
bial peptides, and displays increased activation and expres-
sion of matrix metalloproteinases (MMPs).1,2 There is a criti-
cal interplay between MMPs and antimicrobial peptides in
rosacea skin; for example,MMP-9activates thekallikrein5 ser-
ine protease, leading to generation of LL-37 (the cathelicidin-
derivedantimicrobial peptide),whichmay then further stimu-
late inflammation.1
Matrixmetalloproteinaseshavealsobeen implicated4-6 in
thepathogenesis of Parkinsondisease andother neurodegen-
erative disorders; in experimental models of Parkinson dis-
ease, MMP-3 and MMP-9 levels are increased and contribute
to dopaminergic neuronal loss. A German study7 of 70 pa-
tientswithParkinsondisease showed that rosaceawaspresent
in18.6%of theparticipantsandthat31.4%reportedfacial flush-
ingassociatedwith temperature changes. Inviewof thesedata
linking rosacea and Parkinson disease, we evaluated a pos-
sible association between the 2 conditions in a nationwide
cohort of theDanishpopulation between January 1, 1997, and
December 31, 2011.
Methods
Data Sources and Study Population
Study approval was obtained from the Danish Data Protec-
tionAgency.Reviewbyanethics committee isnot required for
registry studies in Denmark. Conduct of this studywas in ac-
cordance with the Strengthening the Reporting of Observa-
tional Studies in Epidemiology recommendations.8
Inbrief, theDanishCivilRegistrationSystemassigns aper-
manent andunique 10-digit personal identificationnumber to
all citizensatbirthor immigration,whichallows forunambigu-
ous linkage across nationwide registries.9 Moreover, the Dan-
ishCivilRegistrationSystemcontains informationsuchasdate
of birth, sex, and vital status, and Statistics Denmark records
information on tax-reported household income.10 The Danish
National Patient Registery11 contains information on all inpa-
tient and outpatient (ambulatory) hospital contacts since 1978
according to the International Classification of Diseases (ICD)
(prior to 1994 according to the 8th revision [ICD-8] and there-
after according to the International Statistical Classification of
DiseasesandRelatedHealthProblems,TenthRevision [ICD-10]),
andhospital treatment interventions, surgicalprocedures, and
hospital-administered pharmacotherapy are coded as treat-
ment procedure codes. All pharmacy-dispensed prescriptions
in Denmark have been accurately recorded in the Register of
Medicinal Product Statistics since 1994, and all drugs are clas-
sifiedaccording to theAnatomicalTherapeuticChemical (ATC)
classification.12
All Danish citizens 18 years or older were included in the
cohort on January 1, 1997, or the subsequent day that they be-
came that age. Individuals were followed up until December
31, 2011;migration; a diagnosis of Parkinsondisease; or death
fromanycause,whichevercamefirst.Atbaseline,patientswith
prevalent rosacea or Parkinson disease and those with a his-
tory of anti-Parkinson dopaminergic drug use were excluded
toenableaccurateexaminationof the temporal associationbe-
tween exposure to rosacea and the subsequent risk of Parkin-
son disease. Patients with rosacea were identified by the first
documentationof either ahospital (inpatientoroutpatient)di-
agnosis of rosacea (ICD-8 code 695.3 and ICD-10 code L71) or
when they obtained their second prescription of topicalmet-
ronidazole (ATC D06BX01), which is the preferred first-line
treatment for rosacea and is used infrequently for other skin
conditions in Denmark.
End Points
The primary end point of the study was a hospital diagnosis
of idiopathic Parkinson disease (ICD-10 code G20). This diag-
nosishaspreviouslybeenvalidatedwithanaccuracyof82.4%
in the Danish National Patient Register based on the criteria
of theUKParkinsonDiseaseSocietyBrainBank13,14 and thecri-
teria of Gelb et al.15 Moreover, we investigated the initiation
of treatment with anti-Parkinson dopaminergic agents (ATC
codeN04B)asasecondaryendpoint. Inapreviouspopulation-
based study16 of Danish patientswith Parkinson disease, 91%
of the patients received these drugs, and this treatment was
initiated by general practitioners in 75% of the cases on aver-
age 3 years before the patients experienced their first hospi-
tal contact for Parkinson disease.
Covariates
Stroke (ICD-8 codes432-436and ICD-10 codes I63-I64)was in-
cludedasacovariate in theanalyses, aswasuseofantimigraine
Key Points
Question Do patients with rosacea have an increased risk of
Parkinson disease?
Findings This population-based cohort study found a significantly
increased risk of Parkinson disease in patients with rosacea
compared with the general population. Notably, treatment with
tetracycline was associated with a reduced risk of Parkinson
disease.
Meaning Rosacea is an independent risk factor for Parkinson
disease; focus on neurologic symptoms in patients with rosacea
may be warranted.
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agents (ATC code N02C), antidepressants (ATC code N06A),
and anxiolytics (ATC code N05).17-19We tracked smoking his-
torythroughanalgorithmpreviouslydescribed.20Patientswith
a history of alcohol abuse were identified through the use of
pharmacotherapy, treatment interventions, or diagnoses
(eTable 1 in the Supplement). We calculated an index of so-
cioeconomic status between 0 and 4, with 4 indicating the
highest income group, based on the mean gross annual in-
come (standardizedbyage)duringa5-yearperiodbefore study
inclusion. Baseline medication use was calculated up to 6
monthsand informationoncomorbidity, smokinghistory, and
alcohol abusewas collected up to 5 years before the study. In-
formation on covariates was continuously updated through-
out the study period.
Statistical Analysis
Baseline characteristics arepresentedas frequencieswithper-
centages for categorical variables and means (SDs) for con-
tinuousvariables. Incidenceratesweresummarizedper 10000
person-years at risk. Outcomes before an indexdate in the ro-
sacea groupwere allocated to the reference group to obtain a
more accurate exposure-time allocation. For risk estimation,
Poisson regressionmodelswereused to calculate crude-, age-,
and sex-adjusted incidence rate ratios (IRRs), as well as IRRs
adjusted for age, sex, socioeconomic status, smoking, alco-
hol abuse, medication, and comorbidity.
For sensitivity analyses,we retrieved informationonpre-
scriptions for tetracycline (ATC code J01A), which is themost
commonly used oral prescription medication for rosacea in
Denmark, to obtain a reasonably valid estimate of rosacea se-
verity. Thus, patients were classified as having mild disease
from the onset of rosacea until they fulfilled the criteria for
moderate to severe rosacea (ie, initiation of oral tetracycline
therapy, if appropriate). In these analyses, patients were in-
cluded in themild rosacea group until they fulfilled the crite-
ria formoderate to severe rosacea, if appropriate.Patientswere
classified as having ocular rosacea if they had obtained a pre-
scription for hypromellose eyedrops (ATC code S01XA20),
which is often used to treat xerophthalmia in rosacea, andwe
identifiedpatientswith rhinophymaby the ICD-10 codeL71.1.
Because Parkinson disease is associated with seborrheic
dermatitis,wealsoperformedsensitivityanalyses inwhichpa-
tientswith rosaceawere excluded if they had ever (ie, before,
during, or after inclusion) received treatment with ketocon-
azole ina shampooor topical formulation (ATCcodeD01AC08)
or topical corticosteroids (ATC code D07A), which are the
typical treatment modalities for seborrheic dermatitis in
Denmark.21Moreover,we repeatedourprimaryanalysesusing
ahospital dermatologist (inpatient or outpatient) diagnosis of
rosacea (ICD-10 code L71) as our exposure variable. Finally, to
assesswhether tetracycline therapywas associatedwith a re-
ducedriskofParkinsondisease,weperformedanalysesof filled
prescriptions for tetracycline regardless of thepresenceor ab-
senceof rosacea. Statistical significancewas set atP < .05, and
the results are reported as 95% CIs where applicable. All sta-
tistical analyseswereperformedwithStata, version 11.0 (Stata-
Corp) and SAS, version 9.2 (SAS Institute Inc). Data analysis
was conducted from June 26 to July 27, 2015.
Results
From January 1, 1997, to December 31, 2011, the study popu-
lation comprised 5 536422 Danish citizens 18 years or older.
After excluding 7803 and 15920 individuals with rosacea or
Parkinson disease, 32 individuals with both rosacea and Par-
kinson disease, and 39922 individuals with incomplete mi-
gration information, the final cohort included 5472 745 indi-
viduals, with a maximum follow-up of 15 years. The study
flowchart is shown in the Figure, and the baseline character-
istics of the study population are reported in Table 1.
Risk of Parkinson Disease in PatientsWith Rosacea
During the study period, a total of 22 107 and 280 cases of Par-
kinsondiseaseoccurredamongthereferencepopulationandthe
rosaceacohort, respectively (Table2).Of the22387 individuals
whoreceivedadiagnosisofParkinsondiseaseduring the study
period,9812 (43.8%)werewomen,andthemeanageatdiagno-
siswas 75.9 [10.2] years. A total of 93411 individuals in the ref-
erence population and 1169 of those in the rosacea group initi-
ated treatmentwithanti-Parkinsondopaminergic agents in the
2 groups. The incidence rates of Parkinson disease per 10000
person-yearswere3.54(95%CI,3.49-3.59)and7.62(95%CI,6.78-
8.57) in the reference population and in patientswith rosacea,
respectively, and the incidence rates of treatment with anti-
Parkinsondopaminergicagentswere15.03 (95%CI, 14.93-15.12)
and32.17 (95%CI,30.38-34.07), respectively.Parkinsondisease
occurred approximately 2.4 years earlier in patientswith rosa-
cea (mean [SD] age, 73.7 [10.3] years) comparedwith the refer-
encepopulation (76.1 [10.2] years) (P < .001 for thedifference).
The crude IRRof Parkinsondiseasewas 2.15 (95%CI, 1.91-
2.42) in patients with rosacea compared with the reference
population, whereas the fully adjusted (age, sex, socioeco-
nomic status, smoking, alcohol abuse, comorbidity, andmedi-
cation) IRRwas 1.71 (95%CI, 1.52-1.92), as detailed in Table 3.
Figure. Study Flowchart
5 536 422 Danish individuals aged ≥18 y between
January 1, 1997, and December 31, 2011
5 472 745 Population suitable for analysis
63 677 Excluded
39 922 Incomplete information on migration
32 Prevalent rosacea and Parkinson
disease or use of anti-Parkinson
agents
15 920 Prevalent Parkinson disease or
use of anti-Parkinson agents
7803 Prevalent rosacea
5 404 692 Reference
population
68 053 Rosacea
38 305 Mild rosacea 29 748 Moderate to
severe rosacea
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Stratification by sex yielded similar results in fully adjusted
analyses forwomen(IRR, 1.74;95%CI, 1.46-2.07)andmen(IRR,
1.62;95%CI, 1.38-1.91).TheadjustedIRRof treatmentwithanti-
Parkinson dopaminergic agents was 1.59 (95% CI, 1.50-1.69)
in patients with rosacea compared with the reference popu-
lation and remained significant in estimates stratified for sex.
Sensitivity Analyses
In sensitivity analyses, stratificationby thepresumedseverity
of rosacea based onpharmacotherapy revealed a significantly
increased risk of Parkinson disease in patientswithmild rosa-
cea (fully adjusted IRR, 1.82;95%CI, 1.57-2.11) andmoderate to
severerosacea(fullyadjustedIRR,1.84;95%CI, 1.51-2.24)—adis-
easeseveritydosedependencywasnotapparent.Moreover, the
fullyadjusted IRRs revealedan increasedriskof treatmentwith
anti-Parkinsondopaminergic agents inmild (IRR, 1.66; 95%CI
1.53-1.79) andmoderate to severe (IRR, 1.71; 95%CI, 1.56-1.88)
rosacea, and the results remainedsimilar after stratification for
sex (eTable2 in theSupplement).Thefullyadjusted IRRsofPar-
kinson diseasewere 1.57 (95%CI, 1.36-1.82) and 2.03 (95%CI,
1.67-2.48) forpatientswith rosaceawhoneverpickedupapre-
scriptionforhypromelloseeyedropsandpatientswithpresumed
ocular rosacea, respectively.Amongpatientswith rhinophyma
(n = 751), therewere4casesofParkinsondisease,and14patients
initiated treatmentwith anti-Parkinsondopaminergic agents.
ThefullyadjustedIRRsforParkinsondiseaseandtreatmentwith
anti-Parkinson dopaminergic agents were 1.43 (95% CI, 0.54-
3.83;P = .50)and2.05(95%CI, 1.21-3.45;P = .007), respectively,
inpatientswithrhinophyma. Inanalysesof tetracyclineuse (re-
gardless of a rosaceadiagnosis), filledprescriptionsof tetracy-
clineswere associatedwith a2%decrease in the riskof Parkin-
son disease (adjusted IRR, 0.98; 95%CI, 0.97-0.99; P < .001).
Whenweexcluded all patientswith rosaceawhohadever
filled a prescription for ketoconazole (shampooor topical for-
mulation) or topical corticosteroids, the fully adjusted IRR of
both Parkinsondisease (fully adjusted IRR, 1.77; 95%CI, 1.36-
2.31), and treatmentwith anti-Parkinsondopaminergic agents
(fully adjusted IRR, 1.30; 95% CI, 1.13-1.50) remained signifi-
cant. In sensitivity analyses, inwhich the exposurewas ahos-
pital diagnosis of rosacea, the fully adjusted IRR of Parkinson
disease was 2.11 (95% CI, 1.44-3.10). Similarly, when the end
point was initiation of treatment with anti-Parkinson dopa-
minergic agents, the patients with a hospital diagnosis of ro-
sacea had a fully adjusted IRR of 1.58 (95% CI, 1.29-1.92).
Discussion
In thisnationwide studyof theDanishpopulation followedup
to 15 years, we observed a significantly increased risk of new-
onsetParkinsondisease inpatientswith rosaceaandayounger
age at Parkinson disease onset in these individuals. The re-
sults remained consistent in fully adjustedmodels and in sen-
sitivity analyses. Analyses aimed at evaluating the risk of Par-
kinsondisease in rosacea subtypes showeda tendency toward
an increased risk in patients with ocular rosacea. In addition,
regardless of the presence of rosacea, a decreased risk of Par-
kinson disease was found in individuals who had filled pre-
scriptions for tetracyclines.
Fewrisk factors forParkinsondiseasehavebeen identified;
these includeage,male sex,ethnicity, andcertainenvironmen-
talfactors(eg,pesticideexposureandpriorheadinjury[increased
risk]andtobaccosmoking,coffeedrinking,andalcoholconsump-
tion[decreasedrisk]).22Neuroinflammationisanestablishedfea-
ture of Parkinson disease, and increased expression ofMMP-3
andMMP-9has been implicated4,5,23 in the loss of dopaminer-
gic neurons and nigrostriatal pathway degeneration in mouse
modelsofParkinsondisease inwhichgeneticdeletionofMMP-3
andMMP-9 confers significant protection. Furthermore, in an
invivostudy,6apolymorphismintheMMP-9gene,which leads
tohigherpromoter activity,wasassociatedwitha significantly
increasedriskofneurodegenerativedisorders, includingParkin-
son disease. Patients with rosacea also have increased activity
of MMP-1, MMP-3, andMMP-9 in affected skin regions, which
leads to inflammatory tissue damage and extracellular matrix
degradation.24 Increased tear fluidMMPactivity has also been
found in patientswith ocular rosacea,25 and the recognition of
neurogenic rosacea, a rosacea subtype that includes symptoms
such as burning and stinging cutaneous pain, facial flushing,
migraine,neuropsychiatric symptoms, andeven tremor, lends
Table 1. Baseline Characteristics of Study Population
Characteristic
Population, No. (%)
Reference
(n = 5 404 692)
Rosacea
(n = 68 053)
Age, mean (SD), y 40.8 (19.7) 42.2 (16.5)
Sex
Women 2 722 615 (50.4) 45 712 (67.2)
Men 2 682 077 (49.6) 22 341 (32.8)
Socioeconomic status, mean (SD) 2.0 (1.4) 2.5 (1.3)
Smoking, ever 406 181 (7.5) 4644 (6.8)
Alcohol abuse 76 490 (1.4) 737 (1.1)
Stroke 34 983 (0.6) 277 (0.4)
Medication
Antidepressant 152 253 (2.8) 2137 (3.1)
Antimigraine 44 604 (0.8) 1085 (1.6)
Anxiolytic 490 994 (9.1) 6844 (10.1)
Table 2. Incidence Rates of Parkinson Disease and Initiation
of TreatmentWith Anti-Parkinson Dopaminergic Agentsa
Characteristic
Population
Reference Rosacea
Parkinson disease
No. of events 22 107 280
Person-years 62 447 257 367 236
Incidence rate (95% CI) 3.54 (3.49-3.59) 7.62 (6.78-8.57)
Treatment with
anti-Parkinson
dopaminergic agents
No. of events 93 411 1169
Person-years 62 165 293 363 374
Incidence rate (95% CI) 15.03 (14.93-15.12) 32.17 (30.38-34.07)
a Incidence per 10000 person-years in the reference population and rosacea
population.
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further support to a pathogenic link between the 2 diseases.26
However,weemphasize that these findingsarehypothesisgen-
erating; the basis for the pathogenic link between rosacea and
Parkinson disease is unknown. Although theMMPhypothesis
is intriguing, theremaybeothermechanisms that contribute to
theobservedassociation.Forexample,bothrosaceaandParkin-
sondiseasehavebeenassociated1,27with small intestinebacte-
rialovergrowthandHelicobacterpylori infection.Notably,genetic
data appear to show no link between rosacea and Parkinson
disease;however, onlyone relatively small genome-wideasso-
ciation study28 for rosacea has been conducted so far, to our
knowledge,androsaceashouldberegardedanumbrellatermthat
covers several subtypes of the disease.
Tetracyclineshavebeenused inthetreatmentof rosacea for
decades, presumably owing to their ability to reduce kallikrein
5 serineprotease activities by inhibitingMMPexpression inen-
dothelialcellsandkeratinocytesandtherebyblockingthedown-
streamproteolyticcleavageofcathelicidin intoLL-37.29,30 Inthe
present study,wefoundnorosaceadiseaseseverity–dependent
associationwiththeriskofParkinsondiseasewhenmoderate to
severe rosaceawasdefinedby initiationof treatmentwith tetra-
cycline. Although this lack of an association could be the result
ofmisclassificationofrosaceaseverity,anotherexplanationcould
beaneuroprotectiveeffectoftetracyclinethathasbeensuggested
bothinanimalmodels31andaphase2,randomized,double-blind
clinical trial32 of treatmentwith a tetracycline (minocyclinehy-
drochloride) inpatientswithearlyParkinsondisease. Indeed, in
support of this assumption, we found a reduced risk of Parkin-
sondisease inpatientswhohadfilledprescriptions fora tetracy-
cline, and thesedata support a call formoredefinitive random-
ized trialsof thisdrugclass inpatientswithParkinsondisease.31
Weobservedanapproximately4-foldhighernumberofindividu-
als treatedwithanti-Parkinsondopaminergic agents compared
with the number of patients receiving a diagnosis of Parkinson
disease.This increase isprimarilyexplainedby the fact thatour
primaryendpointwasadiagnosisofidiopathicParkinsondisease,
whereastheseagentsarealsousedtotreatsecondaryparkinson-
ism.Typically, 4major criteria areused for thediagnosisofPar-
kinsondisease(bradykinesia,muscularrigidity, tremor,andpos-
tural instability),but therearevariousphenotypic subtypesand
nonmotor features (eg,cognitive impairment,psychiatricsymp-
toms,sleepdisorders,andautonomicdysfunction).15,22 Indeed,
it is tempting tospeculate that, inpatientswithcoexistent rosa-
cea,Parkinsondiseasemaydisplayotherphenotypiccharacter-
istics,anditispossiblethatrosaceaorrosacea-associatedfeatures,
suchasfacial flushing,maycontributetosupportaParkinsondis-
ease diagnosis at an early phase of the disease.
Several strengthsandlimitationsapplytothe interpretation
of thepresent results. TheDanishnationwide registries enable
analysisofavastnumberof individuals, therebyreducingselec-
tionbias (eg,duetoage,sex,orsocioeconomicstatus).Complete
registration,aswellastheprospectivenatureofprescriptiondata
and the ICD diagnostic codes, ensure that recall bias and bias
caused bynonresponse are nearly eliminated. Continuous up-
date of data on covariates during the study period ensured ac-
curateregistrationofpotentialconfoundingfactors,whichcould
changeover time. Inaddition, the resultsof sensitivityanalyses
addcredibility toour findings.Weused ICDcodesandprescrip-
tionsfortopicalmetronidazoleandtetracyclineforrosacea iden-
tificationandseverityclassification, respectively.However, tet-
racycline isalso routinelyused in the treatmentofacnevulgaris
and some infectious diseases; nevertheless, since topicalmet-
ronidazole therapy isnotusedfor theseconditions,anymisclas-
sification related to the use of a tetracycline in this specific co-
hort is likelynegligible. Inaddition,minocycline isnotmarketed
in Denmark. Misclassification was a risk in the ocular rosacea
groupbecauseviscouseyedropsareused formanyconditions.
We attempted to rule outmisclassification of rosacea and seb-
orrheicdermatitisbyexcludingallpatientswhoeverreceivedcor-
ticosteroidsorketoconazole therapy.Notably, thesebumexcre-
tionrate isnot increased inpatientswithrosacea, therebynearly
eliminating thepossibleconcomitantoccurrenceof rosaceaand
seborrheic dermatitis.33Moreover, the observational design of
our study does not allow establishment of causation, and we
cannot ruleout thepossibilityof residual confoundingowingto
increasedexposure tomedicalprofessionals inpatientswithro-
sacea. Finally, the Danish population is primarily of Northern
European descent, which may limit extrapolation to other
ethnicities.
Conclusions
Weobservedasignificantly increased riskofnew-onsetParkin-
sondisease inpatientswith rosacea.Further studiesareneeded
to confirm this observation and its clinical consequences.
Table 3. Incidence Rate Ratios of Parkinson Disease and Initiation of TreatmentWith Anti-Parkinson
Dopaminergic Agents
Characteristic
IRR (95% CI)a
Crude Age and Sex Adjusted Fully Adjustedb
Parkinson disease
Overall 2.15 (1.91-2.42) 2.27 (2.01-2.55) 1.71 (1.52-1.92)
Women 1.71 (1.43-2.03) 2.27 (1.91-2.70) 1.74 (1.46-2.07)
Men 3.15 (2.69-3.70) 2.19 (1.87-2.57) 1.62 (1.38-1.91)
Treatment with anti-Parkinson
dopaminergic agents
Overall 2.14 (2.02-2.27) 1.95 (1.84-2.07) 1.59 (1.50-1.69)
Women 1.58 (1.47-1.70) 1.62 (1.50-1.74) 1.37 (1.28-1.48)
Men 3.35 (3.05-3.69) 2.37 (2.16-2.61) 1.79 (1.63-1.97)
Abbreviation: IRR, incidence rate
ratio.
a All findings were significant at
P < .001.
bAdjusted for age, sex,
socioeconomic status, smoking,
alcohol abuse, comorbidity, and
medication.
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